Welcome to the Hill Group. We study the epidemiology of infections in patients with cancer, transplant recipients, CAR-T cell recipients, and other immunocompromised populations. Over the past few decades, the field of infectious diseases made many advances to vastly improve infection treatment and prevention in immunocompromised cancer patients. However, there remain opportunities for substantial improvements in protecting our patients from known and unrecognized pathogens. Recent advances in molecular virology, drug development, and genetically modified T cell manufacturing open the door to a new era for scientific inquiry to improve patient outcomes.
Our translational research program focuses on improving preventative and treatment strategies for infections. Dr. Joshua Hill’s interest in this field stems from his experiences as a Transplant Infectious Diseases physician, where he witnesses the impact of infections in vulnerable patients. Dr. Hill’s research is highly collaborative with investigators across many disciplines including oncology, pulmonology, pathology, molecular virology, and statistics. Dr. Hill also participates in clinical trials of new therapies to prevent or treat infections in immunocompromised patients.
“The big question in this room is when do we vaccinate? When do we give IVIG? Who needs to get it?”
Dr. Joshua Hill comments on changing cancer therapies.
Infections in immune-compromised patients: 5 new frontiers
Hutch News | Sabin Russell | June 17, 2019